What are the recommended treatment options for metastatic triple‑negative breast cancer, based on programmed death‑ligand 1 (PD‑L1) status, germline breast cancer susceptibility gene (BRCA) mutation status, prior anthracycline or taxane exposure, and the patient’s performance status and organ function?

Treatment for Metastatic Triple Negative Breast Cancer

For metastatic triple-negative breast cancer, treatment selection is driven by PD-L1 status and germline BRCA mutation status, with immune checkpoint inhibitors plus chemotherapy as first-line for PD-L1-positive disease, PARP inhibitors for germline BRCA-mutated disease, and sacituzumab govitecan as the preferred option after progression on taxanes. 1

First-Line Treatment Algorithm

Step 1: Determine PD-L1 Status

If PD-L1 Positive:

• For PD-L1 immune cell positivity (Ventana SP142 assay): Use atezolizumab plus nab-paclitaxel if disease-free interval (DFI) is ≥12 months 1
• For Combined Positive Score (CPS) ≥10: Use pembrolizumab plus chemotherapy (paclitaxel, nab-paclitaxel, or carboplatin-gemcitabine) if DFI is ≥6 months 1, 2

The evidence strongly supports checkpoint inhibitor combinations in PD-L1-positive disease, with ESMO-MCBS scores of 3 for both regimens 1. Note the critical distinction: atezolizumab requires immune cell positivity by SP142 assay (EMA approved, not FDA approved), while pembrolizumab requires CPS ≥10 by 22C3 assay (FDA approved, not EMA approved) 1.

Step 2: If PD-L1 Negative, Check Germline BRCA Status

If germline BRCA1/2 mutation present:

• Preferred options: Olaparib or talazoparib (PARP inhibitors) 1, 3
• Alternative: Carboplatin-based chemotherapy 1

Critical caveat: PARP inhibitors should NOT be withheld from patients without prior anthracycline-taxane treatment—this requirement was regulatory, not biological 1. Post-hoc analysis suggests requiring progression on these agents in the metastatic setting may actually reduce the magnitude of OS benefit 1. PARP inhibitors demonstrated superior health-related quality of life compared to chemotherapy in pivotal trials 1.

If PD-L1 negative and BRCA wild-type:

• Treatment depends on prior exposure, disease presentation, DFI, and performance status 1
• Single-agent chemotherapy is preferred unless visceral crisis or immediately life-threatening disease warrants combination therapy 3
• Preferred single agents: taxanes (weekly paclitaxel 80 mg/m² preferred over every-3-week dosing based on meta-analysis showing OS benefit HR 0.78) 4, anthracyclines (doxorubicin, liposomal doxorubicin), or platinum agents 4

Second-Line and Beyond

After Progression on Anthracyclines and Taxanes

Sacituzumab govitecan is the preferred treatment option after taxanes, with Level I evidence and ESMO-MCBS score of 4 1. The ASCENT trial demonstrated dramatic improvements: median PFS 5.6 vs 1.7 months (HR 0.41) and median OS 12.1 vs 6.7 months (HR 0.48) compared to physician's choice chemotherapy 3. This antibody-drug conjugate targeting Trop-2 is FDA approved but not EMA approved 1.

Key toxicity consideration: Neutropenia occurs in 51% (grade 3+) and diarrhea in 10% (grade 3+), but treatment discontinuation due to adverse events was only 5% 3.

Alternative Second-Line Options

After progression, standard HER2-negative chemotherapy options apply: eribulin, capecitabine, vinorelbine 1. However, recognize that chemotherapy resistance develops quickly in TNBC, and third/fourth-line therapies offer limited benefit 5.

Special Considerations for Germline BRCA-Mutated Disease

Sequencing decisions for BRCA-mutated patients:

• PARP inhibitors can be used in first-through-third-line settings 3
• No direct comparison exists between PARP inhibitors and platinum agents (alone or with ICIs) 1
• Platinum-based chemotherapy shows substantial PFS benefit: median PFS 12.6 months with paclitaxel-carboplatin in BROCADE-3 1
• Single-agent carboplatin was superior to docetaxel only in BRCA-mutated TNBC 1

Sequencing should prioritize:

1. PD-L1 status (if positive, consider ICI-chemotherapy first)
2. Disease burden and presentation
3. Prior treatment response
4. Quality of life considerations (PARP inhibitors superior to chemotherapy) 1

Common Pitfalls to Avoid

1. Do not require prior anthracycline-taxane exposure before offering PARP inhibitors in BRCA-mutated disease—this reduces OS benefit 1

2. Do not use antiandrogen therapy, PI3K, HER2, or AKT inhibitors outside clinical trials—no data support their use in advanced TNBC 1

3. Do not use checkpoint inhibitor monotherapy in later lines—response rates are too low (5-19%) 5, 6

4. Recognize that approximately 25% of patients die before reaching second-line therapy, highlighting the urgency of optimal first-line selection 7

5. Sequential single agents are preferred over combinations unless visceral crisis exists—combinations yield higher response rates but do not improve overall survival 5, 4

Performance Status and Organ Function Considerations

For patients with ECOG performance status ≥2 (10.6% of real-world cohorts), treatment intensity must be reduced 7. Single-agent chemotherapy or best supportive care may be appropriate. The decision to transition to hospice should be individualized based on ongoing goals-of-care discussions, but recognize that third and fourth lines offer minimal benefit 5.

For patients with adequate organ function and good performance status, aggressive treatment with appropriate biomarker-directed therapy is warranted given the poor prognosis (median OS 17.6 months in recent real-world data) 7.